ASX listed PharmAust has taken the next significant step in the development of its exciting canine cancer drug known as Monepantel or MPL. The company this week announced that it had added two new locations to its Phase 2 trials in Australia, one at the Animal Referral Hospital at Homebush, NSW and the other at Queensland Veterinary Specialists in Brisbane.